ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...

The prodrug strategy is basically a smart key that has been designed specifically to unlock the door to cancer treatment only when it reaches the correct target. Utilizing this prodrug strategy ...

Antimalarial drug resistance is a pressing issue in combating the spread of malaria worldwide. In a new study, researchers ...

Consequently, the success of prodrug strategies are very powerful means to improve formulation and delivery properties of drugs. However, prodrug intervention must be an integral part of the drug ...

A bubble of genetic material forms on the end of a mosquito embryo, second from right, as Nijole Jaskins Krene, a specialist ...

MBX Biosciences (MBX) announced the completion of enrollment in its Phase 2 Avail trial of MBX 2109, the Company’s parathyroid hormone peptide ...

The company’s lead drug candidate, MIV-818, is a liver cancer targeted prodrug that Medivir is looking to develop alone in the USA and the EU and through partnerships elsewhere. Swedish ...

Researchers from MBX Biosciences Inc. presented preclinical data on MBX-4291, a prodrug developed as a long-acting GLP-1/GIP co-agonist through MBX’s proprietary Precision Endocrine Peptide (PEP) ...

A new clinical trial from Scripps Research in La Jolla aims to make significant gains in the global fight against malaria by ...

Completion of enrollment in our Phase 2 trial in HP marks a significant milestone for MBX and brings us closer to our goal of delivering a long-acting PTH therapy designed to treat the underlying ...